Breaking Finance News

Biogen Inc (NASDAQ:BIIB) stock price target increased to $309.27, issued a report today by Vetr Inc.

Yesterday Biogen Inc (NASDAQ:BIIB) traded -0.33% lower at $302.77. The company’s 50-day moving average is $299.83 and its 200-day moving average is $287.80. The last closing price is up 5.20% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 1,512,550

In a report released on 11/29/2016 Vetr Inc. increased the stock price target of Biogen Inc (NASDAQ:BIIB) to $309.27 indicating a possible upside of 0.02%.

Previously on Monday November 28, 2016, Vetr Inc. reported on Biogen Inc (NASDAQ:BIIB) increased the target price from $0.00 to $316.41. At the time, this indicated a possible upside of 0.04%.

See Chart Below

Biogen Inc (NASDAQ:BIIB)

Biogen Inc has a 52 week low of $223.02 and a 52 week high of $333.65 with a P/E ratio of 17.12 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its stock price target, a total of 19 brokers have issued a report on the company. The average stock price target is $333.47 with 6 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 9 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Biogen Inc (NASDAQ:BIIB)

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.